Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA-120 in Pruritus Associated with Psoriasis Vulgaris
NCT03322137Phase 2Completed
- Sponsor
- Sienna Biopharmaceuticals
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pegcantratinib in pruritus, Psoriasis vulgaris (PV), sponsored by Sienna Biopharmaceuticals. Started Oct 2017; status: completed.
02
Drugs
pegcantratinib
03
Conditions
pruritusPsoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03322137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322137.